The 4th annual Influenza Congress USA is where key decision makers from pharma, biotech and government come together to plan their development strategies and share best practice with their peers in ‘flu vaccine manufacture.
Last year, we had senior executives from GSK, Novartis, Sanofi Pasteur, CSL and over 100 other companies discussing adjuvant approval in the US, universal vaccine development, cell-based vaccine development, biotech partnering and funding, delivery, experimental challenge studies and novel egg-based vaccine manufacturing.


Can you afford not to be here?
